Recap: Last week, 7 companies went public, 4 of which were from China.
YIBO issued 1.25 million shares at a price of $4 per share, raising $5 million. Rongzhi Group (SUGP) raised $5 million by issuing 1.25 million shares at a price of $4 per share. Jiliang Group (JL) raised $7 million by issuing 1.4 million shares at a price of $5 per share. Haoxi Media (HAO) raised $9.6 million by issuing 2.4 million shares at a price of $4 per share.
CG Oncology (CGON) raised $380 million through the issuance of 20 million shares at a price of $19 per share. BrightSpring Health Services (BTSG) raised $693 million through the issuance of 53.33 million shares at $13 per share (at the same time, the company raised $400 million through the issuance of 8 million tangible shares at $50 per share). ArriVent (AVBP) raised $175 million by issuing 9.72 million shares at $18 per share (originally planned to issue 8.33 million shares).
This week, four companies are currently planning to go public, the most notable of which is Anta Sports' Amalfen, which is planning to raise $1.8 billion.
1. Cell Therapy Biotechnology Company - FibroBiologics Inc.
Planned Availability: January 31, 2024
Exchange: NASDAQ
Stock Code: FBLG
FibroBiologics is a clinical-stage cell therapy biotechnology company focused on developing and commercializing fibroblast-based therapeutics for the treatment of patients with multiple sclerosis, wound healing, and certain cancers, as well as potential life-prolonging applications, including reversal of thymus and spleen degeneration. The company was spun off from its original parent company, FibroGenesis, in 2021.
The size of the fundraising
The company intends to list on NASDAQ through direct listing, without issuing new shares and without raising capital.
Financial data
FibroBiologics尚无收入。
2. Biopharmaceutical company - BioLingus (Cayman) Ltd
Planned Availability: January 31, 2024
Exchange: NASDAQ
Stock Code: SUBL
BioLingus is a Swiss biopharmaceutical company focused on developing drugs for the treatment of diabetes and obesity. The company's core technology enables sublingual delivery of peptides and protein-based drugs for the treatment of chronic diseases and as an alternative to traditional injectable drugs.
The size of the fundraising
The company plans to raise $7.2 million through the issuance of 360,000 shares at a price of $20 per share.
Financial data
BioLingus 尚无收入。
3. Manufacturer of sports equipment and clothing - Amalfen
Planned Launch: February 1, 2024
Exchange: NYSE
Stock Code: AS
Amalfen is a sporting goods company that primarily sells sports equipment, apparel, and footwear. The company's sales network covers 34 countries around the world, of which North America, Europe, Asia and China are its main sales markets.
The size of the fundraising
The company plans to issue 100 million shares in a range of $16 to $18, raising up to $1.8 billion.
Financial data
For the nine months ended September 30, 2023, the company's revenue was $3.053 billion, compared to $2.35 billion in the year-ago quarter, with corresponding net losses of $114 million and $104 million, respectively.
4、滑雪服品牌——Perfect Moment Ltd.
Planned Availability: February 2, 2024 (previously postponed)
Exchange: NASDAQ
Stock Code: PMNT
Perfect Moment postponed its listing to Friday, February 2 and adjusted the size of its offering.
The size of the fundraising
The company plans to issue 1.23 million shares in the $6 to $7 price range (originally planned to raise 2.5 million shares), raising up to about $8.62 million.
Copyright Notice: All original articles of GreenPro Capital must be authorized to be reprinted, and the source and WeChat ID should be indicated at the beginning/end of the article, otherwise legal responsibility will be pursued.